Owing to its overexpression in the vast majority of prostate cancer lesions [2], PSMA has been extensively studied and a number of FDA-approved PSMA-radioligands are currently commercially available for the management of PSMA-avid prostate cancer [3,4]. This evidence concerns the gene FOLH1 and prostate carcinoma.